Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience

다국어 초록 (Multilingual Abstract)

Background: The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy.
Methods: A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between July 2005 and June 2015.
Results: A total of 55 patients (mean age, 51.2 years, 38 women [69.1%]) suspected of having uveoretinal disease owing to the use of chemotherapeutic agents alone were enrolled. Breast cancer was the predominant disease (36.4%); noninfectious anterior uveitis (21.8%) was the most common condition. Bilateral involvement was observed in 16 patients (29.1%).
Although cisplatin (21.8%) was the most commonly used drug, daunorubicin, cytarabine, tamoxifen, toremifene, and imatinib were also frequently used. The median duration until ophthalmologic diagnosis was 208.5 days (range, 19–5,945 days). The proportion of patients with final visual acuity (VA) < 20/40 Snellen VA (0.5 decimal VA) was 32.7%. However, no relationship was observed between final VA < 20/40 and age, sex, therapeutic agents, and metastasis.
Conclusion: Uveoretinal complications were mostly mild to moderate and exhibited a favorable response to conservative therapy. A considerable number of patients exhibited significant irreversible loss of vision after cessation of the causative chemotherapeutic agent.
Ophthalmological monitoring is required during chemotherapy.

참고문헌 (Reference)

1 이상곤, "타목시펜 복용 후 발생한 양안 망막분지정맥폐쇄 1예" 대한안과학회 57 (57): 1806-1811, 2016

2 권진영, "스펙트럼영역 빛간섭단층촬영을 이용한 타목시펜 망막병증의 진단과 경과관찰 증례" 대한안과학회 57 (57): 1656-1660, 2016

3 Schmid KE, "Update on ocular complications of systemic cancer chemotherapy" 51 (51): 19-40, 2006

4 Glueck CJ, "Thrombophilia and retinal vascular occlusion" 6 : 1377-1384, 2012

5 Koulisis N, "The tipping point: tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptor" 3 : 8-13, 2016

6 Cugati S, "Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study" 124 (124): 726-732, 2006

7 Kim LA, "Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms" 55 (55): 4747-4758, 2014

8 McKeown CA, "Tamoxifen retinopathy" 65 (65): 177-179, 1981

9 Wolf SE, "Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma" 13 (13): 561-, 2013

10 Moberg J, "Severe anterior uveitis as a complication of high-dose cytosine-arabinoside" 87 (87): 922-923, 2009

11 van Dijk EH, "Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma" 122 (122): 1907-1916, 2015

12 Liu CY, "Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies" 34 (34): 1261-1280, 2014

13 Kwan AS, "Retinal ischemia with neovascularization in cisplatin related retinal toxicity" 141 (141): 196-197, 2006

14 Eisner A, "Retinal hemorrhages in anastrozole users" 85 (85): 301-308, 2008

15 Doshi RR, "Pseudocystic foveal cavitation in tamoxifen retinopathy" 157 (157): 1291-1298, 2014

16 Choe CH, "Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib" 158 (158): 831-837, 2014

17 Al-Tweigeri T, "Ocular toxicity and cancer chemotherapy. A review" 78 (78): 1359-1373, 1996

18 Vizel M, "Ocular side effects of cancer chemotherapy" 49 (49): 1999-2002, 1982

19 Marmor MF, "Mechanisms of fluid accumulation in retinal edema" 97 (97): 239-249, 1999

20 Vingerling JR, "Macular degeneration and early menopause: a case-control study" 310 (310): 1570-1571, 1995

21 Cho KS, "Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells" 53 (53): 5344-5353, 2012

22 Haan MN, "Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study" 124 (124): 988-992, 2006

23 Song Ee Chung, "Estrogen Antagonist and Development of Macular Hole" 대한안과학회 24 (24): 306-309, 2010

24 Chung H, "Early detection of tamoxifen-induced maculopathy in patients with low cumulative doses of tamoxifen" 1-5, 2010

25 Ryan EH Jr, "Diabetic macular edema associated with glitazone use" 26 (26): 562-570, 2006

26 Togna GI, "Cisplatin triggers platelet activation" 99 (99): 503-509, 2000

27 McCannel TA, "Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer" 132 (132): 1005-1009, 2014

28 Zafeiropoulos P, "Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature" 5 (5): 451-454, 2014

29 Wang MY, "Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy" 130 (130): 367-368, 2000

30 Grewal DS, "Asymmetric anterior uveitis as a delayed complication of treatment with systemic high-dose cytosine-arabinoside: a case report and literature review" 22 (22): 322-325, 2014

31 Najarian DJ, "Annular leukocytoclastic vasculitis associated with sorafenib administration" 9 (9): 697-698, 2010

32 Panebianco M, "A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression" 5 (5): E121-E124, 2014

33 함동식, "A Case of Cystoid Macular Edema Associated with Paclitaxel Chemotherapy" 대한안과학회 26 (26): 388-390, 2012